Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted

Last 30 days: 21 accesses
Last 365 days: 267 accesses
All time: 2029 accesses

Darren M Roberts^* and Jason A Roberts

Critical Care 2007, 11:413 doi:10.1186/cc5786

See related research by Ruelbach et al. http://ccforum.com/content/11/1/R4 and related letter by Brvar and Bunc, http://ccforum.com/content/11/3/415

Accesses